DRUG
L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate
4 hypotheses across 2 therapeutic domains
ALL HYPOTHESES
Repurposing candidates for L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate
Pancreatic cancer 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| Nrf2 | chemoresistance | 0.220 | Mid | unknown | unknown | |
| NRF2 | chemoresistance | 0.220 | Mid | unknown | unknown |
Rheumatoid arthritis 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| Nrf2 | disease activity | 0.220 | Mid | unknown | unknown | |
| Nrf2 | rheumatoid arthritis | 0.220 | Mid | unknown | unknown |
Clinical trials
0 registered trials for L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate
Source: ClinicalTrials.gov
No registered trials found on ClinicalTrials.gov. This could indicate either an unexplored indication or a gap in registry coverage.
Search ClinicalTrials.gov →